TN2014000516A1 - New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents

New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Info

Publication number: TN2014000516A1
Authority: TN; Tunisia
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; thienopyrimidine derivatives; new thienopyrimidine
Prior art date: 2013-12-23

Application number

TN2014000516A

Other languages

English (en)

Inventor

Olivier Geneste

James Edward Paul Davidson

Andras Kotschy

Zoltan Szlavik

Marton Csekei

Attila Paczal

Zoltan Szabo

Szabolcs Sipos

Gabor Radics

Agnes Proszenyak

Alain Bruno

James Brooke Murray

I-Jen Chen

Françoise Perron-Sierra

Balazs Balint

Original Assignee

Servier Lab

Vernalis R&D Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-23

Filing date

2014-12-11

Publication date

2016-03-30

2014-12-11 Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab

2016-03-30 Publication of TN2014000516A1 publication Critical patent/TN2014000516A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Radiology & Medical Imaging (AREA)
Pathology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Transplantation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

TN2014000516A 2013-12-23 2014-12-11 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them TN2014000516A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1363500A FR3015483B1 (fr)	2013-12-23	2013-12-23	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
TN2014000516A1 true TN2014000516A1 (en)	2016-03-30

Family

ID=50829005

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2014000516A TN2014000516A1 (en)	2013-12-23	2014-12-11	New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Country Status (48)

Country	Link
US (3)	US9670227B2 (fr)
EP (1)	EP2886545B1 (fr)
JP (1)	JP5922215B2 (fr)
KR (1)	KR101636401B1 (fr)
CN (1)	CN104725397B (fr)
AP (1)	AP2014008127A0 (fr)
AR (1)	AR098906A1 (fr)
AU (1)	AU2014274644B2 (fr)
BR (1)	BR102014032336B1 (fr)
CA (1)	CA2875226C (fr)
CL (1)	CL2014003444A1 (fr)
CO (1)	CO7210068A1 (fr)
CR (1)	CR20140569A (fr)
CU (1)	CU24309B1 (fr)
CY (1)	CY1118058T1 (fr)
DK (1)	DK2886545T3 (fr)
DO (1)	DOP2014000282A (fr)
EA (1)	EA029601B1 (fr)
ES (1)	ES2594377T3 (fr)
FR (1)	FR3015483B1 (fr)
GE (1)	GEP201706619B (fr)
GT (1)	GT201400297A (fr)
HK (1)	HK1209750A1 (fr)
HR (1)	HRP20161203T8 (fr)
HU (1)	HUE029654T2 (fr)
IL (1)	IL236143A (fr)
JO (1)	JO3193B1 (fr)
LT (1)	LT2886545T (fr)
MD (1)	MD4516C1 (fr)
ME (1)	ME02521B (fr)
MX (1)	MX351581B (fr)
MY (1)	MY185221A (fr)
NI (1)	NI201400150A (fr)
PE (1)	PE20151064A1 (fr)
PH (1)	PH12014000375B1 (fr)
PL (1)	PL2886545T3 (fr)
PT (1)	PT2886545T (fr)
RS (1)	RS55213B1 (fr)
RU (1)	RU2605403C2 (fr)
SA (1)	SA114360144B1 (fr)
SG (1)	SG10201408563UA (fr)
SI (1)	SI2886545T1 (fr)
TN (1)	TN2014000516A1 (fr)
TW (1)	TWI508969B (fr)
UA (1)	UA120341C2 (fr)
UY (1)	UY35915A (fr)
WO (1)	WO2015097123A1 (fr)
ZA (1)	ZA201409365B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2965173A1 (fr)	2014-10-29	2016-05-06	The Walter And Eliza Hall Institute Of Medical Research	Utilisation d'agents therapeutiques
EP3337805A4 (fr) *	2015-05-27	2019-04-03	Pharmascience Inc.	Inhibiteurs de la famille des enzymes kinases tec
FR3037956B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) *	2016-01-19	2018-02-02	Les Laboratoires Servier	Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197055A1 (fr)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Dégronimères hétérocycliques pour la dégradation de protéines cibles
WO2017197051A1 (fr)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
CN109562113A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的螺环降解决定子体
MA45718A (fr) *	2016-07-22	2019-05-29	Servier Lab	Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
WO2018015526A1 (fr)	2016-07-22	2018-01-25	Les Laboratoires Servier	Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
EA201991025A1 (ru) *	2016-10-28	2019-11-29		Липосомальный препарат для применения для лечения злокачественного новообразования
WO2018126898A1 (fr) *	2017-01-05	2018-07-12	河南美泰宝生物制药有限公司	Dérivé de thiénopyrimidine, son procédé de préparation et son application dans la fabrication de médicaments antitumoraux
UY37560A (es)	2017-01-06	2018-07-31	Servier Lab	Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
JOP20190159B1 (ar) *	2017-01-06	2023-09-17	Servier Lab	توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية
EA039621B1 (ru) *	2017-06-09	2022-02-17	Ле Лаборатуар Сервье	Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
CN117959451A (zh)	2017-06-22	2024-05-03	法国施维雅药厂	Mcl-1抑制剂与用于血液癌症的标准治疗的组合，其用途和药物组合物
GB201712282D0 (en) *	2017-07-31	2017-09-13	Nodthera Ltd	Selective inhibitors of NLRP3 inflammasome
BR112020003200A2 (pt) *	2017-08-15	2020-10-06	AbbVie Deutschland GmbH & Co. KG	inibidores macrocíclicos de mcl-1 e métodos de uso
EP3668503A4 (fr) *	2017-08-15	2021-04-07	AbbVie Inc.	Inhibiteurs de mcl-1 macrocyclique et procédés d'utilisation
SG10202106345VA (en) *	2017-08-15	2021-07-29	Abbvie Inc	Macrocyclic mcl-1 inhibitors and methods of use
CN107573360B (zh) *	2017-10-27	2019-08-09	都创(上海)医药科技有限公司	一种多靶点小分子化合物s63845的制备方法
CN111372936B (zh) *	2017-11-23	2022-12-02	北京赛林泰医药技术有限公司	Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) *	2017-12-21	2019-09-20	河南真实生物科技有限公司	噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) *	2018-09-29	2022-04-12	江苏恒瑞医药股份有限公司	嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) *	2018-10-15	2021-05-26	Servier Lab	Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
CN111187277B (zh) *	2018-11-14	2022-04-12	江苏恒瑞医药股份有限公司	噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
TWI849001B (zh) *	2018-11-14	2024-07-21	法商施維雅藥廠	Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
RS65047B1 (sr) *	2018-12-06	2024-02-29	Servier Lab	Novi kristalni oblici tienopirimidina kao inhibitori mcl-1
EP3897631A4 (fr)	2018-12-20	2022-11-23	C4 Therapeutics, Inc.	Dégradation ciblée de protéines
AU2020279230A1 (en)	2019-05-20	2021-12-02	Les Laboratoires Servier	Mcl-1 inhibitor antibody-drug conjugates and methods of use
AR119156A1 (es)	2019-06-17	2021-11-24	Servier Lab	Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma
AR119494A1 (es)	2019-07-29	2021-12-22	Servier Lab	DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
AR119493A1 (es)	2019-07-29	2021-12-22	Servier Lab	Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
US20230116602A1 (en) *	2019-10-03	2023-04-13	California Institute Of Technology	Mcl1 inhibitors and uses thereof
CN113024578A (zh) *	2019-12-09	2021-06-25	首药控股(北京)有限公司	一种mcl1选择性抑制剂的多晶型物及其制备方法
CN113024577B (zh) *	2019-12-09	2023-06-30	首药控股(北京)股份有限公司	一种抗凋亡蛋白选择性抑制剂的制备方法
WO2022090443A1 (fr)	2020-10-30	2022-05-05	Les Laboratoires Servier	Administration et posologie pour une combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1
AU2021386367A1 (en)	2020-11-24	2023-06-22	Les Laboratoires Servier	Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AU2021385349A1 (en)	2020-11-24	2023-06-22	Les Laboratoires Servier	Mcl-1 inhibitor antibody-drug conjugates and methods of use
UY39609A (es)	2021-01-12	2022-08-31	Servier Lab	Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
WO2022169780A1 (fr)	2021-02-02	2022-08-11	Les Laboratoires Servier	Composés bcl-xl protac sélectifs et procédés d'utilisation
WO2022216946A1 (fr) *	2021-04-07	2022-10-13	California Institute Of Technology	Inhibiteurs de mcl1 et leurs utilisations
WO2022255888A1 (fr) *	2021-06-01	2022-12-08	Captor Therapeutics S.A.	Dégradation de protéine ciblée à l'aide de composés bifonctionnels qui se lient à l'ubiquitine ligase et à la protéine mcl-1 cible
US11931424B2 (en)	2021-06-11	2024-03-19	Gilead Sciences, Inc.	Combination MCL-1 inhibitors with anti-body drug conjugates
CN117651554A (zh)	2021-06-11	2024-03-05	吉利德科学公司	Mcl-1抑制剂与抗癌剂的组合
CN119562832A (zh)	2022-05-20	2025-03-04	诺华股份有限公司	Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
IL317101A (en)	2022-05-20	2025-01-01	Novartis Ag	Antibody-drug conjugates of anticancer compounds and methods of using them
IL317102A (en)	2022-05-20	2025-01-01	Novartis Ag	EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of using them
KR20250048158A (ko)	2022-07-08	2025-04-07	르 라보레또레 쎄르비에르	신규 스피로시클로헥산 유도체, 그를 함유하는 제약 조성물 및 항아폽토시스 억제제로서의 그의 용도
WO2025111431A1 (fr)	2023-11-22	2025-05-30	Les Laboratoires Servier	Conjugués anticorps-médicament anti-cd7 et leurs procédés d'utilisation
WO2025111450A1 (fr)	2023-11-22	2025-05-30	Les Laboratoires Servier	Conjugués anticorps anti-cd74-médicament et leurs procédés d'utilisation
WO2025126157A1 (fr)	2023-12-15	2025-06-19	Advesya	Domaines de liaison anti-il-1rap et conjugués anticorps-médicament associés

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4008726A1 (de) *	1990-03-19	1991-09-26	Basf Ag	Thieno(2,3-d)pyrimidinderivate
SI1641803T1 (sl) *	2003-06-11	2009-08-31	Xention Ltd	Tienopirimidinski derivati kot inhibitorji kalijevih kanalov
WO2005069865A2 (fr)	2004-01-13	2005-08-04	Ambit Biosciences Corporation	Derives de pyrrolopyrimidine et analogues et utilisation dans le traitement et la prevention de maladies
US20050288906A1 (en)	2004-06-29	2005-12-29	Drennen James K Iii	Spectroscopic pharmacy verification and inspection system
WO2006004658A2 (fr)	2004-06-29	2006-01-12	Amgen Inc.	Furanopyrimidines
KR20070057792A (ko) *	2004-07-16	2007-06-07	선에시스 파마슈티컬스 인코포레이티드	오로라 키나아제 저해물질로서 유용한 티에노피리미딘
GB0423653D0 (en) *	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
US7576080B2 (en) *	2004-12-23	2009-08-18	Memory Pharmaceuticals Corporation	Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
WO2007046809A1 (fr) *	2005-10-21	2007-04-26	Dow Agrosciences Llc	Composes de thieno-pyrimidine a activite fongicide
EP2114950B1 (fr) *	2006-12-07	2016-03-09	Genentech, Inc.	Composés inhibiteurs de la phosphoinositide 3-kinase et procédés d'utilisation
DE102007027800A1 (de)	2007-06-16	2008-12-18	Bayer Healthcare Ag	Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
EA201000484A1 (ru) *	2007-10-16	2010-12-30	ВАЙЕТ ЭлЭлСи	Тиенопиримидиновые и пиразолопиримидиновые соединения и их применение в качестве ингибиторов киназы mtor и киназы pi3
US8507502B2 (en)	2008-11-10	2013-08-13	National Health Research Institutes	Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
RS55783B1 (sr) *	2010-06-23	2017-07-31	Hanmi Science Co Ltd	Novi derivati fuzionisanog pirimidina za inhibiciju aktivnosti tirozin kinaze
WO2012044993A1 (fr) *	2010-09-30	2012-04-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Composés, compositions pharmaceutiques, et procédés de traitement ou de prévention de maladies ou de troubles neurodégénératifs
CN102464667B (zh) *	2010-11-03	2014-06-04	中国科学院上海药物研究所	一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) *	2011-11-15	2014-10-15	Xention Ltd	Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr)	2012-01-24	2014-02-21	Servier Lab	Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

2013
- 2013-12-23 FR FR1363500A patent/FR3015483B1/fr not_active Expired - Fee Related
2014
- 2014-12-08 JO JOP/2014/0353A patent/JO3193B1/ar active
- 2014-12-09 IL IL236143A patent/IL236143A/en active IP Right Grant
- 2014-12-10 CR CR20140569A patent/CR20140569A/es unknown
- 2014-12-10 PH PH12014000375A patent/PH12014000375B1/en unknown
- 2014-12-11 CA CA2875226A patent/CA2875226C/fr active Active
- 2014-12-11 TN TN2014000516A patent/TN2014000516A1/fr unknown
- 2014-12-12 AP AP2014008127A patent/AP2014008127A0/xx unknown
- 2014-12-12 AU AU2014274644A patent/AU2014274644B2/en active Active
- 2014-12-15 PE PE2014002444A patent/PE20151064A1/es active IP Right Grant
- 2014-12-15 DO DO2014000282A patent/DOP2014000282A/es unknown
- 2014-12-17 CU CUP2014000143A patent/CU24309B1/xx unknown
- 2014-12-18 MY MYPI2014703853A patent/MY185221A/en unknown
- 2014-12-18 CL CL2014003444A patent/CL2014003444A1/es unknown
- 2014-12-18 ZA ZA2014/09365A patent/ZA201409365B/en unknown
- 2014-12-18 MX MX2014015854A patent/MX351581B/es active IP Right Grant
- 2014-12-19 UA UAA201413661A patent/UA120341C2/uk unknown
- 2014-12-19 CN CN201410800069.2A patent/CN104725397B/zh active Active
- 2014-12-19 JP JP2014257658A patent/JP5922215B2/ja active Active
- 2014-12-19 US US14/576,683 patent/US9670227B2/en active Active
- 2014-12-19 NI NI201400150A patent/NI201400150A/es unknown
- 2014-12-19 GE GEAP201413667A patent/GEP201706619B/en unknown
- 2014-12-22 EA EA201401292A patent/EA029601B1/ru unknown
- 2014-12-22 LT LTEP14199533.2T patent/LT2886545T/lt unknown
- 2014-12-22 DK DK14199533.2T patent/DK2886545T3/en active
- 2014-12-22 SI SI201430061A patent/SI2886545T1/sl unknown
- 2014-12-22 EP EP14199533.2A patent/EP2886545B1/fr active Active
- 2014-12-22 GT GT201400297A patent/GT201400297A/es unknown
- 2014-12-22 HU HUE14199533A patent/HUE029654T2/en unknown
- 2014-12-22 MD MDA20140137A patent/MD4516C1/ro active IP Right Grant
- 2014-12-22 SG SG10201408563UA patent/SG10201408563UA/en unknown
- 2014-12-22 ES ES14199533.2T patent/ES2594377T3/es active Active
- 2014-12-22 RU RU2014151850/04A patent/RU2605403C2/ru active
- 2014-12-22 BR BR102014032336-8A patent/BR102014032336B1/pt active IP Right Grant
- 2014-12-22 UY UY0001035915A patent/UY35915A/es active IP Right Grant
- 2014-12-22 SA SA114360144A patent/SA114360144B1/ar unknown
- 2014-12-22 ME MEP-2016-207A patent/ME02521B/fr unknown
- 2014-12-22 PT PT141995332T patent/PT2886545T/pt unknown
- 2014-12-22 PL PL14199533T patent/PL2886545T3/pl unknown
- 2014-12-22 RS RS20160802A patent/RS55213B1/sr unknown
- 2014-12-22 AR ARP140104847A patent/AR098906A1/es active IP Right Grant
- 2014-12-22 TW TW103144845A patent/TWI508969B/zh active
- 2014-12-22 WO PCT/EP2014/078947 patent/WO2015097123A1/fr active Application Filing
- 2014-12-23 KR KR1020140187349A patent/KR101636401B1/ko active Active
- 2014-12-23 CO CO14282098A patent/CO7210068A1/es unknown
2015
- 2015-10-28 HK HK15110667.4A patent/HK1209750A1/xx unknown
2016
- 2016-09-20 HR HRP20161203TT patent/HRP20161203T8/hr unknown
- 2016-09-22 CY CY20161100949T patent/CY1118058T1/el unknown
2017
- 2017-04-20 US US15/492,306 patent/US10278972B2/en active Active
2019
- 2019-03-08 US US16/296,766 patent/US20190201404A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2875226C (fr)	2018-03-13
CL2014003444A1 (es)	2015-10-23
EA201401292A2 (ru)	2015-06-30
AP2014008127A0 (en)	2014-12-31
TWI508969B (zh)	2015-11-21
CO7210068A1 (es)	2015-03-09
HK1209750A1 (en)	2016-04-08
WO2015097123A1 (fr)	2015-07-02
AU2014274644B2 (en)	2019-11-14
MX351581B (es)	2017-10-20
CU24309B1 (es)	2018-01-10
ME02521B (fr)	2017-02-20
CU20140143A7 (es)	2016-07-29
US20190201404A1 (en)	2019-07-04
AR098906A1 (es)	2016-06-22
MX2014015854A (es)	2015-07-22
GEP201706619B (en)	2017-02-10
RU2605403C2 (ru)	2016-12-20
FR3015483B1 (fr)	2016-01-01
JP5922215B2 (ja)	2016-05-24
SG10201408563UA (en)	2015-07-30
DK2886545T3 (en)	2016-09-19
CN104725397B (zh)	2017-11-28
LT2886545T (lt)	2016-09-26
HUE029654T2 (en)	2017-02-28
CA2875226A1 (fr)	2015-06-23
NZ702851A (en)	2016-05-27
KR20150073874A (ko)	2015-07-01
PE20151064A1 (es)	2015-08-08
US10278972B2 (en)	2019-05-07
ZA201409365B (en)	2021-07-28
HRP20161203T1 (hr)	2016-11-04
EA029601B1 (ru)	2018-04-30
UY35915A (es)	2015-07-31
SA114360144B1 (ar)	2015-10-08
EP2886545B1 (fr)	2016-06-29
UA120341C2 (uk)	2019-11-25
JP2015129120A (ja)	2015-07-16
PH12014000375B1 (en)	2017-10-11
ES2594377T3 (es)	2016-12-19
CR20140569A (es)	2016-07-01
HK1211583A1 (en)	2016-05-27
NI201400150A (es)	2015-06-05
FR3015483A1 (fr)	2015-06-26
PH12014000375A1 (en)	2016-06-13
BR102014032336B1 (pt)	2020-10-20
PT2886545T (pt)	2016-08-25
AU2014274644A1 (en)	2015-07-09
CY1118058T1 (el)	2017-06-28
JO3193B1 (ar)	2018-03-08
US9670227B2 (en)	2017-06-06
HRP20161203T8 (hr)	2016-12-30
MY185221A (en)	2021-04-30
TW201529583A (zh)	2015-08-01
US20150175623A1 (en)	2015-06-25
GT201400297A (es)	2017-08-24
MD4516B1 (ro)	2017-09-30
SI2886545T1 (sl)	2016-10-28
MD20140137A2 (ro)	2015-06-30
PL2886545T3 (pl)	2017-03-31
MD4516C1 (ro)	2018-04-30
EP2886545A1 (fr)	2015-06-24
IL236143A (en)	2017-02-28
US20170216293A1 (en)	2017-08-03
BR102014032336A2 (pt)	2016-06-07
DOP2014000282A (es)	2016-06-30
EA201401292A3 (ru)	2015-08-31
RU2014151850A (ru)	2016-07-20
KR101636401B1 (ko)	2016-07-05
CN104725397A (zh)	2015-06-24
RS55213B1 (sr)	2017-02-28

Publication	Publication Date	Title
TN2014000516A1 (en)	2016-03-30	New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018502515A1 (en)	2019-09-30	New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en)	2019-04-12	New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
MY190561A (en)	2022-04-27	New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018502516B1 (en)	2023-10-13	New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201890124A1 (ru)	2018-05-31	Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201400833A1 (ru)	2014-12-30	Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
PH12015501996A1 (en)	2016-01-11	Heterocyclic compounds and uses thereof
MX336214B (es)	2016-01-12	Derivados de pirrolotriazinona como inhibidores de pi3k.
EA201890123A1 (ru)	2018-05-31	Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
PH12015500813B1 (en)	2015-06-08	Pyrrolotriazinone derivatives as pi3k inhibitors
MY173258A (en)	2020-01-09	New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
MX378194B (es)	2025-03-10	Compuestos organicos.
IN2014MN02598A (fr)	2015-07-24
PH12014000179A1 (en)	2016-01-18	New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
JO3310B1 (ar)	2018-09-16	مشتقات إندوليزين جديدة وطريقة لإنتاجها وتركيبات صيدلانية تحتوي عليها
GEP20156423B (en)	2016-01-11	9-[4-(3-chlor-2-fluorphenylamino)-7-methoxy- quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, usage thereas drug, and production thereof
GEP201706675B (en)	2017-05-25	Imidazo-triazine derivatives as pde10 inhibitors
IN2015DN00950A (fr)	2015-06-12